Please login to the form below
ALGS
This page shows the latest ALGS news and features for those working in and with pharma, biotech and healthcare.
Silver lining as Shire rare disease programme hits a setback
Alagille syndrome candidate fails to meet phase II targets. Shire suffered a setback in its rare disease pipeline after a candidate for the genetic disease Alagille syndrome (ALGS) failed its objectives ... ALGS is mainly caused by mutation or deletion
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Manager – Healthcare advertising
-
Salary TBC
-
Events Executive
-
DOE
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Senior Medical Writer
-
Competitive salary plus benefits
- Client Services Director- Flexible Working
-
Negotiable
Subscribe to our email news alerts
- Novartis eyes potential new indication for Cosentyx
- J&J's Tremfya filed for approval in US for psoriatic arthritis
- Envision Pharma Group relocates to support expansion
- Biogen loses another pipeline drug to toxicity concerns
- AZ, Merck’s Lynparza scores market-expanding clinical success
- AbbVie/Allergan's merger faces public opposition
PMHub
M&F Health
M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...
Latest intelligence
- Report: Customer experience, shaping digital healthcare
- In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
- Encouraging signs in biomarker R&D
- The cancer immunotherapy firms ramping-up biomarker R&D...
- Programmatic methodology and why you should be using it
- What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Quick links
Infographics
